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PAD Is No Longer
Related to Rodney
The Beneﬁt of Statins*
Michael R. Jaff, DO
Boston, Massachusetts
When Jacob Cohen was born in Babylon, New York, in
1921, few would have expected that his pleas for “respect”
would have resulted in a long and successful career in
comedy as Rodney Dangerﬁeld. However, those who have
been managing atherosclerotic syndromes for decades
appreciate that until recently, peripheral artery disease
(PAD) patients may have been referred to as victims of
“Dangerﬁeld’s syndrome.” Little research was focused on
the role of medical interventions for PAD until recently,
and PAD rarely received attention in the scientiﬁc litera-
ture compared to patients with other atherosclerotic syn-
dromes. Identiﬁcation and aggressive medical therapy forSee page 682patients with PAD have lagged behind their counterparts
with coronary artery disease (CAD). Data on the role of
“standard” medical therapy for PAD patients, including the
use of antiplatelet therapy and statins, have been woefully
inadequate compared with data on patients with CAD (1).
Despite the recommendations of experts, the routine use
of statins in patients with PAD is far less common than
among patients with CAD (2). The beneﬁts of statin
therapy in PAD have been suspected for decades. In 1 series
of 1,374 patients with PAD followed for a mean of 6.4
years, all-cause and cardiac-related mortality rates were lower
in the patients on higher statin doses with resultant lower
low-density lipoprotein (LDL) levels (3). The Heart Pro-
tection Study advanced our understanding of the intensity of
statin therapy by evaluating >20,000 patients with or
without known PAD (4). In this series, the relative reduc-
tion in the ﬁrst peripheral vascular event was 16%, regardless
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Vascular.In the paper byWestin et al. (5) in this issue of the Journal,
the current real-world management of the most severe
manifestations of PAD is highlighted. All of the patients
had, by deﬁnition, critical limb ischemia (CLI). Disap-
pointingly, only 65% were receiving statins. Not only did the
patients on statins have lower LDL cholesterol levels and
have fewer major adverse cardiovascular events and death, but
interestingly, these patients also had improved amputation-
free survival and more durable results if treated with endo-
vascular therapy for infrapopliteal occlusive disease.
There have been studies suggesting an improvement in
physical function in patients with intermittent claudication
treated with statins (6–9). A Cochrane review reported by
pooling all the published series that 6-min walk and pain-free
walking distances actually improved among those PAD pa-
tients treated with statins (10). However, the mechanism(s)
whereby statins may actually improve arterial outcomes in
PAD remain uncertain. In a small series of 68 patients with
PAD treated with statins with or without ezetimibe, despite
an impressive reduction in LDL cholesterol and improve-
ment in the ankle-brachial index, there was no improvement
in calf muscle perfusion or physical functioning (11).
It is exciting to learn through this retrospective, single-
center propensity analysis that aggressive statin therapy
may not only reduce myocardial infarction, stroke, and
death, but may actually improve limb survival in the most
advanced PAD patients. As the authors mention, the major
limitation of widespread adoption of statins in CLI is the
lack of data on the duration of statin therapy and compliance
of patients on the medications. This certainly provides
motivation for a prospective analysis of patients with all
manifestations of PAD, including those with ischemic rest
pain and nonhealing ischemic ulcerations, treated with statin
therapy to aggressively low LDL cholesterol levels and
include imaging of treated arterial segments. If the data of
such a protocol mirrored those of Westin et al., the power
of statin therapy would be raised to a level equal to that of
patients treated for CAD, leaving only Mr. Cohen as the
disrespected one.
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